Bedfont Scientific Ltd. announces ODM deal with large medical supplier in China

MAIDSTONE, U.K. - Aug. 25, 2021 - PRLog -- Shenzhen Century Kangdu Medical Technology Co., Ltd. was established in 2017. The company is located in Pingshan District, Shenzhen, focusing on the R&D, manufacturing and sales of respiratory testing medical devices. Kangdu has signed an Original Design Manufacturer (ODM) agreement with Bedfont for the new NObreath® Fractional exhaled Nitric Oxide (FeNO) monitor.

FeNO is a biomarker for airway inflammation, helping in the control and diagnosis of asthma and also the differentiation between asthma and other respiratory diseases.  Measuring FeNO through breath analysis, making the process quick, simple and non-invasive for both the GP and the patient. Interpreting FeNO levels aids in identifying patients who do/do not require on-going treatment whilst also differentiating between allergic (eosinophilic) and non-allergic asthma, and if used daily, FeNO measurements can help to predict exacerbations and attacks.

The ODM agreement for NObreath® means Bedfont designs and manufactures the monitor and Kangdu distributes the product under their branding, EZbreath.

Mr. Zhu Chun Ming, Managing Director at Kangu, commented, "Bedfont's NObreath® is a very innovative and patient-friendly device; we are excited to integrate this monitor into our existing range of high-quality respiratory medical devices and help Bedfont expand its reach through the medical market in China."

Jason Smith, Managing Director at Bedfont, adds, "We are looking forward to working with Kangdu to help improve asthma diagnosis and management in China. This new strategic partnership is a huge step for Bedfont as it will enable us to access this new market and help us to further highlight FeNO breath testing and its benefits."